Assess couple's infertility as appropriate prior to treatment initiation. Evaluate women & give appropriate specific treatment for hypothyroidism, adrenocortical insufficiency, hyperprolactinemia & pituitary or hypothalamic tumours before starting therapy. Intended for single SC inj only. After treatment administration, no additional FSH-containing product should be given prior to stimulation day 8. Monitor ovarian response to reduce risk of OHSS. Risk of ovarian torsion; multiple pregnancies & birth; ectopic pregnancy; thromboembolic events. Incidence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. Reports of ovarian & other reproductive system neoplasms in women who have undergone multiple treatment regimens for infertility treatment. Combination w/ GnRH agonist is not recommended. May cause false +ve HCG pregnancy test if the test is administered during the ovarian stimulation portion of the ART cycle. May cause dizziness that may affect ability to drive & use machines. Not recommended in women w/ renal insufficiency. Not indicated during breast-feeding.
Sign Out
